Peter Attia· MD
What I would not use is that Pro oxidative biomarker that way too many people are is lipoprotein phospholipase a2 first of all the data is pretty poor most people don't even know the only thing the FDA has given that approval for is as a screening test in primary prevention never ever for anybody on a lipid modulating drug or on who has known coronary atherosclerosis for the simple reason at Mendelian randomization schon of the year level of LPP la2 activity or mass has nothing to do with how comes sort of like the HDL cholesterol story and even more important there have been two mega trials where pharmaceutical industry has developed LPP le2 inhibitors gave them to patients shut down LP PLA - activity drastically reduce LP PLA - mass levels plummeted no outcome reduction whatsoever